News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PreScience Labs Announced that the FDA Accepts IND Application for Novel Oncology Drug



7/24/2013 9:44:57 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

POTOMAC, Md.--(BUSINESS WIRE)--PreScience Labs, LLC (“PreScience”) announced today that the U.S. Food and Drug Administration (“FDA”) has approved its Investigational New Drug (“IND”) application for Phase I clinical evaluation of its anti-cancer drug 3-bromopyruvate (“3-BrPA” or “PSL-001”). This Phase I clinical trial will be conducted in patients with primary and/or metastatic liver cancer.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES